GlassScriptPhysician profile
Barbara A Mcquinn
NPI 1578592192
$6,928.61
in general payments reported to CMS, 2019-2025
49 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,716 · 2020: $2,171 · 2021: $1,142 · 2022: $1,077 · 2023: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $821 · Education: $1.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $821.22 |
| Education | $1.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $755.44 | 2019-2023 | Austedo Xr |
| Abbvie INC. | $478.39 | 2019-2023 | |
| Allergan, INC. | $451.02 | 2019-2021 | |
| Ucb, INC. | $399.39 | 2019-2021 | |
| Biogen, INC. | $379.98 | 2019-2023 | Vumerity, Plegridy, Avonex |
| Avanir Pharmaceuticals, INC. | $300.49 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $281.98 | 2019-2023 | Rytary |
| Amgen INC. | $280.41 | 2019-2023 | Aimovig |
| Greenwich Biosciences, INC. | $266.71 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $259.97 | 2019-2023 | Ongentys, Ingrezza |
| Eisai INC. | $222.94 | 2019-2023 | |
| Acadia Pharmaceuticals INC | $211.69 | 2019-2023 | Nuplazid |
| Livanova USA, INC. | $188.99 | 2019-2021 | |
| Sk Life Science, INC. | $181.25 | 2020-2023 | Xcopri |
| Lilly USA, LLC | $170.27 | 2019-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Mcquinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.